Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ABX464 in HIV Patients on Boosted Darunavir
NCT02735863Phase 2Completed
- Sponsor
- Abivax
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of obefazimod in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Abivax. Primary endpoint: Number of Participants With Adverse Events up to 4 months. Started May 2016; status: completed.
02
Drugs
obefazimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02735863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735863.